CMS Rejects HHS Call For Off-Label Avastin Endorsement

Law360, New York (April 24, 2012, 8:22 PM EDT) -- Medicare administrators are shooting down recommendations in a government study released Monday that adds fresh ammunition to claims off-label use of cancer drug Avastin for eye disease could save taxpayers billions of dollars.

The report by the Office of the Inspector General in the U.S. Department of Health and Human Services rekindles a smoldering debate pitting Genentech Inc.'s Avastin against Novartis AG's Lucentis. The former pharmaceutical is thought to be cheap and effective when used for wet age-related macular degeneration, but only the latter is formally...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.